Company intelligence / Profile preview

Mitokinin

San Francisco, California, United States

Ownership: Private
Employees: ~12
Development stage: Other

Overview

Mitokinin was developing a novel class of kinase-targeted neo-substrates focusing on PINK1 activation to treat neurodegenerative diseases. Their lead compound, a selective PINK1 activator, aimed to address mitochondrial dysfunction in Parkinson's Disease.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Partnerships

Amgen (for Golden Ticket award)Pfizer Ventures (as an investor)

Beyond the preview

Go deeper on Mitokinin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitokinin.

Explore the full profile